JAN 0 8 2002 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 1 0 2002 CH CENTER 1600/29(

RADEMIn re Applicant:

T. ARAZI

Serial No.:

09/963,761

Filed:

SEPT. 27, 2001

For: VECTORS FOR EXPRESSING
HETEROLOGOUS PEPTIDES AT THE AMINOTERMINUS OF POTYVIRUS COAT PROTEIN,
METHODS FOR USE THEREOF, PLANTS
INFECTED WITH SAME AND METHODS OF
VACCINATION USING SAME

Examiner:

Customer service center -IPED

Group Art Unit:

1642

Attorney

Docket:

1686/4

Commissioner of Patents and Trademarks Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY

Sir:

This is in response to the United States Patent and Trademark Office Action mailed November 15, 2001, which response is being made on or before January 15, 2002 and for which no extension fees are due. Please amend the above-identified application as follows: In the Specification:

Please replace the submitted figure 7 with attached figures 7a, 7b and 7c.

Please replace the originally submitted sequence listing with the attached sequence listing.

<u>REMARKS</u>

This response is intended to provide materials necessary to allow examination on the merits to begin. While the Applicant filed a copy of the "Sequence Listing" in computer readable format, that copy does not comply with the requirements of 37 C.F.R.1.822 and or 1.823. Therefore, a new copy of the sequence listing in computer readable format is attached hereto.





The Applicant States that the content of the sequence listing information recorded in

computer readable form is identical to the written (paper) sequence listing and includes no

new matter. In an effort to insure compliance with USPTO guidelines, the newly submitted

sequence listing has been prepared using software supplied by the USPTO. As a result, the

format, but not the listed sequences, is slightly different from the originally submitted

sequence listing. Copies of the original advisory action and a supplementary "RAW

SEQUNCE LISTING ERROR REPORT" are attached to this response.

Further, the applicant attaches hereto Figures 7 a-c which were omitted in the original

submission. The text of the filed specification provides ample support for these figures. The

applicant states that submission of these figures does not constitute an introduction of new

matter.

The applicant respectfully requests that examination on the merits proceed.

Respectfully submitted,

Attorney for Applicant

Registration No. 33,883

Date: January 3, 2002







United States Patent and Trademark Office

JAN 1 0 2002

UNITED STATES PA

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/963,761

09/27/2001

Tzahi Arazi

1686/4

CONFIRMATION NO. 1790

FORMALITIES LETTER

OC000000007074705*

DR. MARK FRIEDMAN LTD. c/o Bill Polkinghorn Discovery Dispatch 9003 Florin Way Upper Marlboro, MD 20772

Date Mailed. 11/15/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a)

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1 825(d) Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000)
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1 823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d)

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

The following item(s) appear to have been **omitted** from the application:

• Figure(s) 7A, 7B, 7C described in the specification

I. Should applicant contend that the above-noted omitted item(s) was in fact deposited in the U.S. Patent and Trademark Office (USPTO) with the nonprovisional application papers, a copy of this Notice and a petition (and \$130.00 petition fee (37 CFR 1.17(h))) with evidence of such deposit must be filed within TWO MONTHS of the date of this Notice. The petition fee will be refunded if is determined that the item(s) was received by the USPTO.

II. Should applicant desire to supply the omitted item(s) and accept the date that such omitted item(s) was filed in the USPTO as the filing date of the above-identified application, a copy of this Notice, the omitted item(s) (with a supplemental oath or declaration in compliance with 37 CFR 1.63 and 1.64 referring to such items), and a petition under 37 CFR 1 182 (with the \$130.00 petition fee (37 CFR 1.17(h)) requesting the later filing date **must** be filed within **TWO MONTHS** of the date of this Notice.

III. The failure to file a petition (and petition fee) under the above options (I) or (II) within **TWO MONTHS** of the date of this Notice (37 CFR 1.181(f)) will be treated as a constructive acceptance by the applicant of the application as deposited in the USPTO. **THIS TWO MONTH PERIOD IS NOT EXTENDABLE UNDER 37 CFR 1.136(a) or (b)** In the absence of a timely filed petition in reply to this Notice, the application will maintain a filing date as of the date of deposit of the application papers in the USPTO, and original application papers (*i.e.*, the original disclosure of the invention) will include only those application papers present in the USPTO on the date of deposit.

In the event that applicant elects not to take action pursuant to options (I) or (II) above (thereby constructively electing option (III)), amendment of the specification to renumber the pages consecutively and cancel incomplete sentences caused by any omitted page(s), and/or amendment of the specification to cancel all references to any omitted drawing(s), relabel the drawing figures to be numbered consecutively (if necessary), and correct the references in the specification to the drawing figures to correspond with any relabelled drawing figures, is required. Any drawing changes should be accompanied by a copy of the drawing figures showing the proposed changes in red ink. Such amendment and/or correction to the drawing figures, if necessary, should be by way of preliminary amendment submitted prior to the first Office action to avoid delays in the prosecution of the application.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE